Late toxicity printout — Sarcoma

Cited monitoring paradigm

Acute: ACS names fatigue, field dermatitis, hair loss in the field, and pain or swelling. Late: skin and fibrosis change, lymphedema, heart problems after anthracyclines, neuropathy, fertility effects, sexuality changes, lasting fatigue, bowel or bladder problems after abdomen or pelvis treatment, hearing loss after high-dose platinum chemo, and cognitive change after chemo. Monitor: field wound or infection; later heart checks after some sarcoma chemo; echoes after cardiotoxic chemo; lung function tests after some chemo or transplant; lasting fatigue or sleep problems; bowel or bladder change after abdomen or pelvis treatment; hearing change after high-dose platinum chemo; fertility after pelvis, belly, or spine treatment; sexuality or body-image change; memory, thinking, or focus change after chemo. Those names are not encoded. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Not a fracture-risk or second-primary screening engine.

Not a fourth printout section. Cadences stay placeholders. Named tests are not encoded.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

ACS long-term and follow-up-care lists, named not encoded. Not a fourth printout section.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

ACS follow-up-care named contents. Not a fourth printout section.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS follow-up-care named steps. Not a fourth printout section.

Acute toxicities

During or shortly after RT. ACS early side effects.

• Fatigue — ACS names fatigue as a common early RT side effect.ACS-radiation-body
• Radiation dermatitis — ACS names redness, irritation, swelling, or peeling in the treated field.ACS-radiation-body
• Hair loss in the field — ACS names hair loss only in the treated area.ACS-radiation-body
• Pain or swelling in the field — ACS names treatment-area symptoms during or shortly after RT. Not a fracture-risk engine.ACS-radiation-body

Late toxicities

Months to years after RT. ACS delayed effects.

ACS long-term late names: Heart problems after anthracyclines · Heart problems after some cardiotoxic treatments · Peripheral neuropathy after chemo · Cognitive impairment after brain RT or chemo · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Bowel or bladder problems after abdomen or pelvis treatment · Hearing loss after high-dose platinum chemo · Cavities and tooth loss after chemo

• Skin look and feel — ACS names darker, thicker, firmer, or more sensitive treated skin.ACS-radiation-body
• Fibrosis in the field — ACS names later tissue firmness after RT.ACS-radiation-body
• Lymphedema if the field includes a limb or basin — ACS names fluid buildup after some field RT. Not a stage engine.ACS-radiation-body
• Bone and soft-tissue late change — ACS bone after-treatment page names short-term and long-term side effects, including later heart checks after some chemo. Official age-band percent-of-cases cells are not restated.ACS-bone-follow
• Soft-tissue follow-up late effects — ACS soft-tissue after-treatment page names late or long-term side effects on the survivorship care plan. Those months are not encoded. Female death rate stays a rate per 100k.ACS-soft-tissue-follow
• Heart problems after anthracyclines — ACS long-term page names anthracyclines among cardiotoxic treatments. Problems may show up years later. No dose reconstruction.ACS-long-term-effects
• Heart problems after some cardiotoxic treatments — ACS long-term page names heart problems after anthracyclines, cisplatin, checkpoint inhibitors, VEGF inhibitors, HER2-directed therapy, hormone therapy or ADT, or radiation to the lung, chest, or breast. Problems may show up years later. Named only on fields that already cite a cardiotoxic treatment. Not a heart-dose or echo-interval engine.ACS-long-term-effects
• Peripheral neuropathy after chemo — ACS long-term page names numbness, tingling, or pain in the feet and hands after chemo, immunotherapy, targeted therapy, surgery, or radiation. Named only on fields that already name chemo and do not already carry a CRC-specific neuropathy row. Not a neuropathy-score engine.ACS-long-term-effects
• Cognitive impairment after brain RT or chemo — ACS long-term page names changes in memory, thinking, or focus after brain radiation or chemo, also called chemo brain or brain fog. New or worsening change should be reported right away. Named only on the brain field and on fields that already name chemo. Not a cognitive-screening engine.ACS-long-term-effects
• Fertility after pelvis, belly, or spine RT — ACS long-term page names fertility effects after chemo or radiation to the pelvis, belly, or spine. Named only on abdomen or pelvis fields that do not already carry their own fertility row. Not a fertility-preservation engine.ACS-long-term-effects
• Sexuality after cancer treatment — ACS long-term page names changes to sex organs, sexual drive, sexual function and well-being, and body image after cancer treatment. Named only on abdomen or pelvis fields that do not already carry their own sexual-function names. Not a sexual-function engine.ACS-long-term-effects
• Cancer-related fatigue that lasts — ACS long-term page names cancer-related fatigue as the most common long-term effect, lasting months or years and not always improving with rest. Sleep problems are also named and may have more than one cause.ACS-long-term-effects
• Joint or muscle pain after some treatments — ACS long-term page names joint or muscle pain after chemo, steroids, or hormone therapy. Symptoms may improve over time. People who are not physically active may have a higher risk. Not a rehab-interval engine.ACS-long-term-effects
• Mental health and distress after treatment — ACS long-term page names anxiety, depression, post-traumatic stress, loneliness, and fear of recurrence among common mental-health effects after cancer treatment. Not a mental-health screening engine.ACS-long-term-effects
• Bowel or bladder problems after abdomen or pelvis treatment — ACS long-term page names bowel blockage from adhesions, urinary retention, urinary or bowel incontinence, and UTIs after surgery or radiation to the abdomen or pelvis. Those names apply only when the field or surgery includes the abdomen or pelvis. Not an endoscopy or cystoscopy-interval engine.ACS-long-term-effects
• Hearing loss after high-dose platinum chemo — ACS long-term page names hearing loss after high-dose platinum chemo, often permanent, and may name an ENT or audiology referral. Named only on fields that already name platinum or cisplatin. Not an audiogram-interval engine.ACS-long-term-effects
• Cavities and tooth loss after chemo — ACS long-term page names tooth-enamel damage after chemo, which raises cavity and tooth-loss risk. Named only on fields that already name chemo. Not a dental-calendar engine.ACS-long-term-effects
• Second cancers after radiation or chemo — ACS adult second-cancers hub says a second cancer is a new unrelated cancer, not a recurrence. Radiation is linked to later AML, CML, ALL, or MDS, and to solid tumors that more often show up 10 years or more later, including breast, lung, thyroid, or bone and soft-tissue sarcomas. Chemo is linked most often to MDS and AML; ALL is also named. Chemo is named as a greater leukemia risk factor than radiation. Those names are not encoded. Bone and soft-tissue sarcomas are named among later solid tumors after radiation. Complementary to the bone and soft-tissue after-treatment pages. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Not a second-primary screening engine.ACS-second-cancers-adults
• Follow-up care plan after treatment — ACS follow-up-care page, developed with ASCO review, names a cancer treatment summary and a survivorship care plan, plus watching for recurrence and for a second cancer. Regular cervical, breast, colorectal, or lung screening may be named. Those plans and screens are not encoded. Echoes after cardiotoxic chemo and lung function tests after some chemo or transplant are named. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.ACS-follow-up-care

Named conditions to monitor

Red flags and suggested follow-up cadence placeholders. Not a personal calendar.

ACS follow-up tests named here: Echoes after cardiotoxic chemo · Lung function tests after some chemo or a stem-cell or bone-marrow transplant

• Field wound or infection

  Field wound or infection — ACS says to tell the care team about skin changes so irritation and infection can be managed. On-treatment skin-care placeholder — not encoded.

  ACS-radiation-body

• Later heart checks after some sarcoma chemo

  Later heart checks after some sarcoma chemo — ACS bone after-treatment page names later heart checks after some chemo. Echo placeholder only. No cumulative doxorubicin-equivalent dose. Official age-band percent-of-cases cells are not restated.

  ACS-bone-follow

• Soft-tissue sarcoma follow-up

  Soft-tissue sarcoma follow-up — ACS after-treatment page names follow-up visits after treatment, which may include exams, lab tests, x-rays, and scans. Official age-band percent-of-cases cells are not restated. Cited SEER stub only. Female death rate stays a rate per 100k. Not encoded.

  ACS-soft-tissue-follow

• Second-cancer testing after soft-tissue sarcoma

  Second-cancer testing after soft-tissue sarcoma — ACS after-treatment page says experts do not recommend any additional testing to look for second cancers in patients without symptoms. Named later-cancer sites are not encoded. Symptom-directed placeholder. Official lifetime figures are not restated.

  ACS-soft-tissue-follow

• Treatment-related second-cancer risk after some bone sarcoma therapy

  Treatment-related second-cancer risk after some bone sarcoma therapy — ACS bone after-treatment page names second-cancer risk after some chemo and radiation, including named anthracyclines, alkylators, platinum drugs, and etoposide. Named drugs and field checks are not encoded. Official age-band percent-of-cases cells are not restated.

  ACS-bone-follow

• Nerve and fertility effects after some sarcoma therapy

  Nerve and fertility effects after some sarcoma therapy — ACS long-term page names peripheral neuropathy and fertility effects after chemo or radiation to the pelvis, belly, or spine. Named effects are not encoded. Not a fertility-preservation or neuropathy-score engine.

  ACS-long-term-effects

• Cancer-related fatigue or sleep problems that last

  Cancer-related fatigue or sleep problems that last — ACS long-term page names cancer-related fatigue as the most common long-term effect, plus sleep problems after treatment. Named months-or-years window is not encoded. Placeholder only — not a fatigue-score engine.

  ACS-long-term-effects

• Joint or muscle pain after chemo, steroids, or hormone therapy

  Joint or muscle pain after chemo, steroids, or hormone therapy — ACS long-term page names joint or muscle pain after those treatments and says symptoms may improve over time. Named activity and rehab steps are not encoded. Placeholder only — not a rehab-interval engine.

  ACS-long-term-effects

• Anxiety, depression, or fear of recurrence after treatment

  Anxiety, depression, or fear of recurrence after treatment — ACS long-term page names those as common types of mental distress among cancer survivors and says very worried, depressed, or angry feelings can affect daily life. Named support steps are not encoded. Placeholder only — not a mental-health screening engine.

  ACS-long-term-effects

• Bowel or bladder change after abdomen or pelvis treatment

  Bowel or bladder change after abdomen or pelvis treatment — ACS long-term page names bowel blockage, trouble emptying the bladder, leakage, or UTIs after surgery or radiation to the abdomen or pelvis. Symptom-directed placeholder — not encoded. Not an endoscopy or cystoscopy-interval engine. Named only when the field includes the abdomen or pelvis.

  ACS-long-term-effects

• Hearing change after high-dose platinum chemo

  Hearing change after high-dose platinum chemo — ACS long-term page names hearing loss after high-dose platinum chemo and may name an ENT or audiology referral. Named referral is not encoded. Placeholder only — not an audiogram-interval engine.

  ACS-long-term-effects

• Cavity risk after chemo

  Cavity risk after chemo — ACS long-term page names a dentist at least once every 6 months after treatments that raise cavity and tooth-loss risk, including chemo. Named 6-month dental interval is not encoded here. That named interval stays on the head-and-neck printout. Not a dental-calendar engine.

  ACS-long-term-effects

• Fertility after pelvis, belly, or spine treatment

  Fertility after pelvis, belly, or spine treatment — ACS long-term page names fertility effects after chemo or radiation to the pelvis, belly, or spine and may name a specialist referral. Referral placeholder — not encoded. Not a fertility-preservation engine.

  ACS-long-term-effects

• Sexuality or body-image change after treatment

  Sexuality or body-image change after treatment — ACS long-term page says to talk with the cancer care team or primary care provider about sexuality changes. A referral to a sex educator, counselor, therapist, or sexual-health specialist may be named. Referral placeholder — not encoded. Not a sexual-function engine.

  ACS-long-term-effects

• New or worsening memory, thinking, or focus

  New or worsening memory, thinking, or focus — ACS long-term page says to tell the care team right away about new or worsening memory, thinking, or focus changes after brain radiation or chemo. Named effects are not encoded. Not a cognitive-screening engine.

  ACS-long-term-effects

• New heart symptoms years after cardiotoxic treatment

  New heart symptoms years after cardiotoxic treatment — ACS long-term page names later heart problems after some cardiotoxic treatments and asks which specialist should follow those effects. Referral placeholder — not encoded. Not a heart-dose or echo-interval engine. No cumulative doxorubicin-equivalent dose.

  ACS-long-term-effects

• Second-cancer awareness after radiation or chemo

  Second-cancer awareness after radiation or chemo — ACS adult second-cancers hub names later MDS or leukemia after some chemo or radiation, and later solid tumors after radiation. Bone and soft-tissue sarcomas are named among later solid tumors after radiation. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Named several-year and 10-year windows are not encoded. Symptom-directed placeholder — not a second-primary screening engine.

  ACS-second-cancers-adults

• Ask which late-effect tests belong on the follow-up plan

  Ask which late-effect tests belong on the follow-up plan — ACS follow-up-care page names special tests after some treatments. Examples named here are echoes after cardiotoxic chemo, and lung function tests after some chemo or a stem-cell or bone-marrow transplant. Those named tests are not encoded. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Named yearly and age-30 intervals are not encoded. Placeholder only — not a second-primary screening engine.

  ACS-follow-up-care